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Abstract
 
CD4
 
  
 
T cell responses are associated with disease control in chronic viral infections. We ana-
lyzed human immunodeficiency virus (HIV)-specific responses in ten aviremic and eight
viremic patients treated during primary HIV-1 infection and for up to 6 yr thereafter. Using a
highly sensitive 5-(and-6)-carboxyfluorescein diacetate-succinimidyl ester–based proliferation
assay, we observed that proliferative Gag and Nef peptide-specific CD4
 
  
 
T cell responses were
30-fold higher in the aviremic patients. Two subsets of HIV-specific memory CD4
 
  
 
T cells
were identified in aviremic patients, CD45RA
 
  
 
CCR7
 
  
 
central memory cells (Tcm) producing
exclusively interleukin (IL)-2, and CD45RA
 
  
 
CCR7
 
  
 
effector memory cells (Tem) that pro-
duced both IL-2 and interferon (IFN)-
 
 
 
. In contrast, in viremic, therapy-failing patients, we
found significant frequencies of Tem that unexpectedly produced exclusively IFN-
 
 
 
. Longitudinal
analysis of HIV epitope–specific CD4
 
  
 
T cells revealed that only cells that had the capacity to
produce IL-2 persisted as long-term memory cells. In viremic patients the presence of IFN-
 
 
 
–
producing cells was restricted to periods of elevated viremia. These findings suggest that
long-term CD4
 
  
 
T cell memory depends on IL-2–producing CD4
 
  
 
T cells and that IFN-
 
 
 
only–producing cells are short lived. Our data favor a model whereby competent HIV-specific
Tcm continuously arise in small numbers but under persistent antigenemia are rapidly induced
to differentiate into IFN-
 
  
 
only–producing cells that lack self-renewal capacity.
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Introduction
 
Infection by HIV-1 inexorably leads to severe immuno-
deficiency caused mostly by the loss of CD4
 
  
 
T cells (1, 2).
The deletion of CD4
 
  
 
T cells is thought to be a conse-
quence of the cytopathic effect of HIV although several
studies have highlighted the important contribution of
hyperimmune activation to the loss of CD4
 
  
 
T cells (3).
Analyses of T cell dynamics during chronic HIV and simian
immunodeficiency virus (SIV) infection using ex vivo
staining with Ki67, as well as in vivo BrdU or [
 
3
 
H]glucose
incorporation, have demonstrated the high turnover rate of
CD4
 
  
 
T cells in humans (4, 5) and in nonhuman primates
(6, 7). Whether enhanced T cell turnover is the conse-
quence of CD4 depletion or its cause has been debated.
Recent analysis of the immune response in the natural hosts
of SIV, the sooty mangabey, and African green monkey,
suggest that the absence of disease progression in these
species is causally related to their failure to develop a general-
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 CFSE, 5-(and-6)-carboxyfluorescein diacetate-
succinimidyl ester; HAART, highly active antiretroviral therapy; ICS,
intracellular cytokine staining; LCMV, lymphocytic choriomeningitis
virus; SIV, simian immunodeficiency virus; Tcm, central memory CD4
 
 
 
T cell(s); Tem, effector memory CD4
 
  
 
T cell(s). 
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ized state of immune activation and elevated T cell turn-
over despite high levels of SIV viremia (8). Moreover, in
some patients infected with HIV-2, which is associated
with a less aggressive clinical course, high levels of immune
activation comparable to those seen in HIV-1 infection
may also develop and are then associated with comparable
levels of CD4 cell depletion (9).
In this report, we have investigated the impact of the
constant activation and turnover of HIV-specific CD4
 
 
 
memory cells in HIV-1–infected patients on their pheno-
type and function, both as a model and because of the po-
tential implications for understanding the immunopatho-
genesis underlying disease progression. CD4
 
  
 
T cells are
involved in protection from many viral infections (10).
They play a major role in the induction of the immune re-
sponse through their capacity to produce IL-2, to activate
APCs via CD40–CD40L interaction, and to provide help
to responding CD8
 
  
 
T cells (11–14). In HIV-infected pa-
tients, Rosenberg et al. (15) demonstrated strong CD4
 
  
 
T
cell proliferative responses against the HIV-1 Gag protein
in long-term nonprogressors and in early highly active anti-
retroviral therapy (HAART)-treated patients. The magni-
tude of HIV-specific proliferative response was inversely
correlated to plasma viral load, suggesting that the absence
of an HIV-specific proliferative response is due to the dele-
tion of HIV-specific CD4
 
  
 
T lymphocytes. Indeed, HIV-
specific CD4
 
  
 
T cells are the preferential targets of infec-
tion by HIV-1 (16). However, Pitcher et al. (17) showed
that Gag-specific CD4
 
  
 
T lymphocytes capable of produc-
ing IFN-
 
  
 
were detectable in most HIV-infected patients
including viremic individuals, whereas such cells were un-
detectable in patients treated during chronic infection. Re-
cently, several studies have shown discrepancies between
the frequencies of HIV-specific IFN-
 
 
 
–producing CD4
 
  
 
T
cells and HIV-specific lymphoproliferation in viremic
HIV-infected patients (18–20), suggesting that the absence
of HIV-specific CD4
 
  
 
T cell proliferative responses is due
to dysfunction of HIV-specific CD4
 
  
 
T cells rather than
their absolute loss. Whether this dysfunction is related to
maturation/differentiation of HIV-specific CD4
 
  
 
T cells or
to other mechanisms is not known.
Memory CD4
 
  
 
T cells have been subdivided into central
(Tcm) and effector (Tem) memory based on the expression
of CCR7, CD62L, and CD45RA, and on their ability to
produce cytokines and proliferate. CD4
 
  
 
Tcm were shown
to produce exclusively IL-2 and have a high capacity to
proliferate, whereas Tem produce mainly IFN-
 
  
 
and have
limited proliferative capacity (21). To determine the impact
of HIV-1 infection on the persistence and maturation of
the HIV-specific memory CD4
 
  
 
T cell response, we mon-
itored HIV epitope–specific CD4
 
  
 
T cells using a 5-(and-
6)-carboxyfluorescein diacetate-succinimidyl ester (CFSE)-
based proliferation assay as well as by intracellular cytokine
staining (ICS) in HAART-treated patients that had been
infected from 1 to up to 6 yr and who were successful or
not in controlling their viremia. We show that persistent
HIV-1 generates a high frequency of IFN-
 
 
 
  
 
HIV-specific
CD4
 
  
 
T cells, lowers the frequency of IL-2–producing
cells, and interferes with the establishment and/or mainte-
nance of long-lived memory.
 
Materials and Methods
 
Study Population.
 
All patients signed informed consent ap-
proved by the Royal Victoria Hospital review board. The
aviremic and viremic patients were treated with HAART within
the first 6 mo of infection. The approximate onset of HIV-1 in-
fection was determined by clinical symptoms and the detuned as-
say (22). Aviremic patients (
 
n 
 
  
 
10) maintained undetectable viral
loads, measured using the Amplicor HIV-1 Monitor UltraSensi-
tive Method (Roche) from the initiation of HAART and during
up to 72 mo of follow-up. Viremic patients (
 
n 
 
  
 
8) had several
viral rebounds (median, 5; range, 4–7) due to interruption/failure
of anti–HIV-1 drug treatment. The median CD4 T cell count for
the aviremic patients was 671 cells/
 
 
 
l at the time of apheresis.
The median viral load of the viremic patients was 45,295 copies/
ml and the median CD4 T cell count 485 cells/
 
 
 
l. Patients’ char-
acteristics are described (see Table I).
 
CD4
 
  
 
T Cell Proliferation Assay.
 
Gag (HXB2) and Nef
(BRU) 15-mer peptides were obtained from the National Insti-
tutes of Health (NIH) AIDS Research & Reference Reagent
Program (Rockville, MD) and the Canvac Core Facility
(Montréal, Canada), respectively. Estimated purity of the peptides
was 
 
 
 
90% as measured by HPLC and mass spectrometry. Indi-
vidual peptides were diluted in DMSO (Sigma-Aldrich) at 100
mg/ml and stored at 
 
 
 
80
 
 
 
C. PBMCs were isolated from periph-
eral blood or apheresis donor packs by sodium diatrizoate density
centrifugation (Amersham Biosciences). Frozen samples were
cryopreserved using patients’ plasma supplemented with 10%
DMSO. Cryopreserved samples were maintained in liquid nitro-
gen and thawed for use in the proliferation assay. 10–50 
 
  
 
10
 
6
 
PBMCs were labeled with a predetermined concentration of
CFSE (Molecular Probes). The final concentration of CFSE used
for PBMC labeling varied between 0.7 and 1.5 
 
 
 
M. Cells were
washed twice in PBS and resuspended in RPMI media supple-
mented with 10% human serum (Sigma-Aldrich). 10
 
6
 
/ml CFSE-
labeled PBMCs were incubated in 96–deep well plates (Nunc) in
the presence of Gag or Nef peptide pools (2 ug/ml/peptide) or
10 
 
 
 
g/ml individual peptides. 1 
 
 
 
g/ml CMV lysate (Biowhit-
taker) or 50 ng/ml SEA (Toxin Technology) were used as posi-
tive controls. Cells were stained with anti-CD4 APC and anti-
CD3 PE (Becton Dickinson) after 6 d of in vitro incubation at
37
 
 
 
C, 5% C0
 
2
 
. A minimum of 3–5 
 
  
 
10
 
5 
 
events, gated on CD3
 
 
 
CD4
 
  
 
viable T lymphocytes, were collected on a FACSCali-
bur™ dual laser cytometer (Becton Dickinson) and analyzed us-
ing FlowJo
 
® 
 
software (TreeStar).
Previous reports indicated that CD4
 
  
 
T cells begin to divide
after 36–48 h (23, 24) of stimulation with average doubling time
of 18 
 
  
 
7.5 h (unpublished data). Based on these numbers, it is
possible to estimate that between five to nine divisions occurred
during 6 d of in vitro proliferation. Similar estimates of cell divi-
sion numbers have been reported (25–27). Indeed, by comparing
baseline frequencies of CD4
 
  
 
T cells producing IL-2 to the per-
centages of peptide-specific CFSE
 
low 
 
CD4
 
  
 
T cells in aviremic
HIV-1–infected patients, we were able to estimate that seven to
eight divisions of epitope-specific CD4
 
  
 
T cells occur within the
6-d CFSE test. Therefore, the baseline frequency corresponding
to 1% of CFSE
 
low 
 
CD4
 
  
 
T cells after 6 d would range between
0.007 to 0.003% of the total CD3
 
  
 
CD4
 
  
 
T cells. 
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ICS.
 
Frozen PBMCs were rapidly thawed in complete media
and 10
 
6 
 
PBMCs were distributed in 96–deep well plates and incu-
bated at 37
 
 
 
C for 2 h before stimulation. PBMCs were stimulated
with 10 
 
 
 
g/ml peptides, anti-CD28, and anti-CD49d (1 
 
 
 
g/ml;
BD Biosciences) for 12 h. Golgi-stop (Becton Dickinson) was
added after 2 h of stimulation. Cells were collected and stained
with anti-CD4 PerCP (Becton Dickinson), anti–IFN-
 
  
 
PE (BD
Biosciences), anti–IL-2 FITC (BD Biosciences), and anti-CD69
APC (Becton Dickinson). The six color analysis was performed us-
ing the following antibodies: CD4-APC-Cy7 (DakoCytomation),
biotinylated CCR7 (Becton Dickinson) followed by streptavidin
PE-Cy7 (DakoCytomation), IL-2 PE (Becton Dickinson), IFN-
 
 
 
APC (BD Biosciences), and CD69 FITC (BD Biosciences). A
minimum of 1–3 
 
  
 
10
 
5 
 
events, gated on CD4
 
  
 
lymphocytes, were
collected on LSR dual laser cytometer (Becton Dickinson) and an-
alyzed using FlowJo™ software (TreeStar).
 
Human Class II Molecular MHC Typing.
 
HLA typing was
performed using conventional genotyping SSP-PCR low/high
resolution kits (QIAamp Kit; QIAGEN). In brief, DNA was ex-
tracted from blood using the QIAamp 96 blood kit followed by
an intermediate resolution SSOP-PCR typing and high resolu-
tion SSP-PCR subtyping.
 
Statistical Analysis.
 
The exact Mann-Whitney and Spearman
correlation statistical tests were performed using Prism V2 soft-
ware (GraphPad). Differences were considered statistically signifi-
cant when P 
 
  
 
0.05.
 
Results
 
High Proliferative Capacity of HIV-specific CD4
 
  
 
T Cells in
Aviremic Compared with Viremic Patients.
 
The overall fre-
quency of HIV-specific CD4
 
  
 
T cells decreases throughout
HAART treatment to the point where these cells become
undetectable by current assays (17, 28–33). Previous reports
have suggested that early treatment leads to the preserva-
tion of HIV-specific proliferative CD4
 
  
 
T cell responses
(15, 34–36), although adequate characterization of the
memory T cell compartment has not been addressed. To
monitor HIV peptide–specific CD4
 
  
 
T cell responses, we
developed a highly sensitive proliferation assay based on the
labeling of T cells with the cell tracking dye CFSE. To
study the function and the maintenance of HIV-specific
memory CD4
 
  
 
T cells, we initially performed a cross-sec-
tional study on patients who had been infected for up to 6
yr and who had been treated early after infection. Because
the CD4 T cell count is usually low in untreated patients,
proliferative CD4
 
  
 
T cell responses were analyzed in
aviremic HAART-successful and in viremic HAART-fail-
ing patients. Both groups have similar CD4 T cell count
but differ primarily by the presence or absence of viral re-
bounds. The CD4 T cell analysis was performed after an
 
Table I.
 
Patients’ Characteristics
 
Patient HIV RNA
 
a
 
CD4 count
 
b
 
HLA-DRB1 HAART
 
c
 
Treatment
 
d
 
Group 1
12C
 
 
 
50 677
 
*
 
0901, 
 
*
 
11 48 DdI, D4T EFV
12B
 
 
 
50 667
 
*
 
0101, 
 
*
 
07 60 D4T, 3TC, RIT
11C  50 1,037 *0101, *08 48 EFV (DMP 266-06), IND
13C  50 461 *0401, *11 48 D4T, 3TC, IND
10C  50 789 *11, *15 12 RIT, IND, Comb (AZT/3TC)
09B  50 400 *0401, *1501 13 D4T, 3TC, NFV
02B  50 604 ND 14 3TC, VER, NFV, D4T
03C  50 1,064 *0401, *07 12 3TC, AZT, ABC
11B  50 574 *13, *15 12 Comb (AZT/3TC), NFV
07B  50 443 *07, *15 12 D4T, 3TC, RIT
Group 2
111 45,000 420 *13, *13 72 AZT, 3TC
112 30,000 529 *03, *04 60 AZT, 3TC
113 65,000 606 *11, *15 24 D4T, 3TC, IND
114 40,000 406 *0103, *07 60 D4T, 3TC, IND
115 10,000 771 *07, *11 60 3TC, AZT, EFV
116 33,452 420 *14, *14 48 3TC, AZT, EFV
117 65,007 344 *04, *13 48 ND
118 73,902 386 ND 72 3TC, AZT, ABC
Group 1, patients with therapy success and no viral rebounds; Group 2, patients with therapy failure due to several viral rebounds throughout therapy.
aCopies of HIV-1 RNA/ml of plasma at the time of study.
bPeripheral CD4  T lymphocyte count at the time of study.
cDuration of current regimen (months).
dAntiretroviral drug abbreviations: ABC, abacavir; AZT, zidovudine; D4T, savudine; EFV, efavirenz; IND, indinavir; NFV, nelfinavir; 3TC, lamivudine.Inhibition of HIV-specific CD4  T Cell Memory in Viremic Patients 1912
average of 28 and 55.5 mo of HAART, respectively (Table
I, Group 1 and Group 2). In aviremic patients, HIV-spe-
cific CD4  T cell responses were analyzed at 48 (Table I,
patients 11C, 12C, and 13C) and 60 (Table I, patient 12B)
mo after HAART initiation. A matrix (37) of 170 overlap-
ping peptides (15-mer with an 11–amino acid overlap)
spanning the entire Gag (122 peptides) and Nef (48 pep-
tides) proteins was generated. PBMCs from HAART-
treated aviremic and viremic patients were stimulated with
peptide pools (10–12 peptides/pool) and CD4  T cell pro-
liferation was assessed using the CFSE-based proliferation
assay. Single Gag and Nef peptides able to induce the high-
est percentage of CFSElow CD4  T cells were selected in
every patient. Control experiments in uninfected individu-
als showed that these peptides did not induce  0.05% of
CFSElow  cells. Proliferative responses scoring  0.1% of
CD3  CD4  CFSElow cells were considered positive. We
observed major differences in the proliferative capacity of
HIV-specific CD4  T cells from viremic versus aviremic
patients (Fig. 1). For example, although CD4  T cells from
aviremic patients 12C, 12B, and 11C expanded extensively
after stimulation with the G067 peptide (20, 5, and 6% CF-
SElow CD4  T cells, respectively), PBMCs from viremic
patients 111, 112, and 113 barely proliferated in response to
this peptide (0.13, 0.12, and 0.26% CFSElow CD4  T cells,
respectively). Assuming that all HIV-specific T cell precur-
sors undergo proliferation at similar rates, the percentages
of CFSElow cells approximately reflect baseline frequencies
of 0.0005, 0.0005, and 0.001% of G067 responding CD4 
T cells in viremic patients 111, 112, and 113 (Table III and
refer to Materials and Methods), respectively, as compared
with frequencies of 0.11, 0.05, and 0.07% in aviremic pa-
tients 12C, 12B, and 11C, respectively (Table II and refer
to Materials and Methods). The reduction in CD4  T cell
proliferative responses in viremic patients is not due to
differences in HLA-DR allelic polymorphism between
aviremic and viremic patients because the G067 peptide
binds 13 different HLA-DR alleles (38). The reduced pro-
liferation of CD4  T cells in viremic patients was also ob-
served with other Gag peptides such as G054, G008, and
G065 (0.23, 0.3, and 0.53%, respectively), whereas PBMCs
from aviremic patients maintain the ability to proliferate in
response to many Gag peptides such as G076 (8% in patient
12B) or G065 (5% in patients 12C and 11C). Similar results
were obtained with Nef peptides with a significant prolifer-
ative capacity of CD4  T cells in aviremic but not viremic
Figure 1. Ability of HIV-specific CD4  T cells to proliferate in
vitro. (a) Comparison between aviremic (12C, 12B, and 11C) and
viremic (111, 112, and 113) patients for the ability of CD4  T cells to
proliferate in vitro. PBMCs from aviremic and viremic patients were
labeled with CFSE and stimulated for 6 d with the selected Gag pep-
tides G067 (WIILGLNKIVRMYSP), G076 (YKTLRAEQASQEVKN),
G065 (PVGEIYKRWIILGLN), G054 (DRVHPVHAGPIAPGQ), and
G008 (YKLKHIVWASRELER). The numbers indicated in each quad-
rant are the percentage of CD3  CD4  CFSElow T cells. NS, media
stimulation; SEA, staphylococcal enterotoxin. The data are representa-
tive of five different experiments. (b) Proliferative response of CFSE-
labeled PBMCs from aviremic ( ) and viremic ( ) patients to HIV,
CMV lysate, and SEA antigen. Two peptides (Gag and Nef peptides)
were chosen per patient for their ability to induce the highest percent-
age of CFSElow CD4  T cells in both aviremic and viremic patients.
The sequences of the peptides are listed in Tables II and III. Median
percentage of CFSElow HIV-1 CD4  T cells in aviremic patients is 9.2%
(n   20; range, 6–20%), whereas the median response in viremic patients
is 0.3% (n   16; range, 0.2–0.5%). CMV lysate median CD4  T cell
responses are 11% in aviremic (n   10; range, 5–30%) and 12.5% in
viremic patients (n   8; range, 5–32%). Median CD4  T cells responses with SEA stimulation are 50% in aviremic (n   8; range, 44–60%) and
47.5% in viremic patients (n   8; range, 40–60%). Statistical significance is determined by the exact Mann-Whitney test.Younes et al. 1913
patients (Tables II and III). The results were reproduced in
additional seven aviremic and five viremic patients as indi-
cated in Fig. 1 b. The median percentage of CFSElow CD4 
T cells in aviremic patients was 9.2% (n   20; range,
6–20%), whereas the median response in viremic patients
was 0.3% (n   16; range, 0.2–0.5%). Our results indicate
that the reduced proliferative response in viremic patients is
neither restricted to a single peptide nor to a single HIV
protein because reduced HIV-specific proliferative re-
sponses were detected with Gag- as well as Nef-derived
peptides (Fig. 1 b and Table III). Overall, a 30-fold differ-
ence in the proliferative capacity of epitope-specific CD4 
T cells was observed between aviremic and viremic pa-
tients. Of note is the fact that the negative impact of HIV
viremia on CD4  T cell proliferation was observed only in
HIV-specific T cell responses. Indeed, analysis of CMV- or
SEA-specific responses in aviremic and viremic patients
failed to show any statistical difference in the frequency of
CFSElow cells (P   0.1 and 0.6, respectively; Fig. 1 b).
Altogether, these results demonstrate that HIV-specific
CD4  T cell proliferative response is impaired in patients
who are viremic. This is either due to the absence of HIV-
specific CD4  T cells, to the virus-mediated killing of the
proliferating cells during the in vitro stimulation, or to in-
trinsic proliferative defect of these cells. Moreover, the re-
sults clearly indicate that CD4  T cell proliferative re-
sponses are maintained in HAART-treated patients even 5
yr after treatment initiation, suggesting that the control of
viremia allows the persistence of a pool of long-term HIV-
specific CD4  memory T cells.
High Frequency of HIV-specific CD4  T Cells Producing
IFN-  in Viremic Patients. Next, we investigated the cyto-
kine secretion potential of HIV-specific CD4  T cells in
aviremic and viremic patients. As shown in Fig. 2 a, stimula-
tion of PBMCs from aviremic patient 12C with 2 Gag pep-
tides induced the production of both IL-2 (0.1 and 0.07%)
and IFN-  (0.05 and 0.03%). In contrast, stimulation of
PBMCs from viremic patient 111 with the same peptides led
to the exclusive production of IFN-  (0.2 and 0.4%; Fig. 2 b).
Analysis of intracellular IL-2 and IFN-  production in ten
aviremic and eight viremic patients demonstrates that HIV-
specific CD4  T cells secreting IL-2 are only detected in
aviremic patients (median, 0.05%; range, 0.1–0.04; Fig. 2 c
and Table II). HIV-specific responses in all aviremic patients
included CD4  T cells producing either IL-2 alone (median,
0.03%; range, 0.02–0.05) or both IL-2 and IFN-  (median,
Table II. Proliferation and Cytokine Production by HIV Peptide–specific CD4  T Cells in Aviremic Patients
Patient Peptide Sequence
Percent
CFSElow CD4  DBLFa CD69  IL-2  CD69  IFN-   IL-2 /IFN-   IL-2  IFN-  
12C G067 WIILGLNKIVRMYSP 20 0.11 0.1 0.05 0.05 0.05  0.01
G065 PVGEIYKRWIILGLN 15 0.08 0.07 0.03 0.03 0.04  0.01
12B G076 YKTLRAEQASQEVKN 8 0.05 0.05 0.02 0.02 0.03 0.03
G067 VDLSHFLKEKGGLEG 6 0.05 0.05 0.02 0.02 0.03  0.01
11C G065 IYKRWIILGLNKIVR 8 0.07 0.07 0.03 0.03 0.04  0.01
G067 WIILGLNKIVRMYSP 7.5 0.04 0.05 0.02 0.02 0.03  0.01
13C G067 DRVHPVHAGPIAPGQ 7 0.03 0.05 0.02 0.02 0.03  0.01
N010 LEKHGAITSSNTAAT 6.5 0.03 0.04 0.02 0.02 0.02  0.01
10C N012 SSNTAATNAACAWLE 7.5 0.05 0.04 0.02 0.02 0.02  0.01
G072 IRQGPKEPFRDYVDR 6 0.03 0.04 0.02 0.02 0.02  0.01
09B G057 PGQMREPRGSDIAGT 10 0.05 0.06 0.03 0.03 0.03  0.01
G040 KVVEEKAFSPEVIPM 7 0.03 0.05 0.02 0.02 0.03  0.01
02B N010 LEKHGAITSSNTAAT 9 0.05 0.06 0.03 0.03 0.03  0.01
G055 PVHGPIAPGQMREP 7.5 0.04 0.04 0.02 0.02 0.02  0.01
03C N048 LAFHHVARELHPEYF 11 0.06 0.07 0.04 0.04 0.03  0.01
G040 KVVEEKAFSPEVIPM 6.3 0.04 0.04 0.02 0.02 0.02  0.01
11B G065 IYKRWIILGLNKIVR 15 0.08 0.08 0.04 0.04 0.04  0.01
N012 SSNTAATNAACAWLE 8 0.04 0.05 0.02 0.02 0.03  0.01
07B N017 EVGFPVIPQVPLRPM 12 0.06 0.07 0.04 0.04 0.03  0.01
G057 PGQMREPRGSDIAGT 6.7 0.03 0.04 0.02 0.02 0.02  0.01
Median 9.2 0.051 0.056 0.026 0.026 0.029 NA
Values of percent CFSElow CD4  are the medians of five independent experiments. The percentages of cytokine production were measured after 12 h
after stimulations of patients’ PBMCs with HIV-specific peptides. The data depicted are the medians of three separate experiments. Values  0.01
indicate undetectable frequencies. NA, not applicable.
aDBLF, deduced baseline frequency derived from the 6-d CFSE-based proliferation assay.Inhibition of HIV-specific CD4  T Cell Memory in Viremic Patients 1914
0.03%; range, 0.02–0.05; Table II). Interestingly, we could
not detect a subset of cells producing only IFN-  in most of
the aviremic patients (Table II). This is in sharp contrast to
the cytokine production capacity of CD4  T cells from
viremic patients that secrete exclusively IFN-   (median,
0.2%; range, 0.1–0.4; Fig. 2 C and Table III).
These data demonstrate that the reduction of prolifera-
tive responses in viremic patients is not due to the absence
of HIV-specific CD4  T cells because high frequencies of
IFN- –producing CD4  T cells were detected by ICS after
stimulation with HIV peptides. Our results also show that
upon viral control, HIV-specific IFN-   IL-2  CD4  T
cells are not detected in aviremic HAART-successful pa-
tients. Rather, cells producing IL-2 or both IL-2 and IFN- 
are detected even several years after the infection.
IL-2 Restores the Proliferation of HIV-specific IFN-   IL-2 
CD4  T Cells. The results illustrated in Fig. 2 clearly
show the significant differences in cytokine production pat-
terns observed between viremic and aviremic patients.
Taken together these results and those illustrated in Fig. 1
suggest that the inability to produce IL-2 might be responsi-
ble for the absence of proliferative responses in viremic pa-
tients. Supporting this hypothesis, a strong positive correla-
tion was observed (P   0.0001, R   0.81, n   20) between
the baseline frequencies of Gag and Nef peptide–specific
CD4  T cells, as measured by the ability to produce IL-2
and the percentage of CFSElow epitope–specific CD4  T
cells in aviremic patients after in vitro stimulation (Fig. 3 a).
Because HIV-specific CD4  T cells in aviremic patients
produce both IL-2 and IFN-  when stimulated with the in-
dicated peptides, a positive correlation (P   0.0001, R  
0.86) was also generated when plotting together frequencies
of IFN- –secreting CD4  T cells and of CFSElow cells gen-
erated after in vitro peptide stimulations (Fig. 3 b). This is in
contrast to IFN-   CD4  T cells in viremic patients where
no correlation was found (P   0.4) between the frequency
of HIV-specific IFN- –producing cells at baseline and the
proliferative response after 6 d. The absence of correlation is
most likely due to lack of IL-2 production by HIV-specific
CD4  T cells from viremic patients.
To test if the presence of IL-2 could restore the prolifer-
ation of these cells, we stimulated CD4  T cells from
viremic patients (111, 112, and 113) with a pool of peptides
containing the G067 peptide, which gave strong IFN- 
responses in these three patients (Table III), in the pres-
ence of exogenous IL-2. As illustrated in Fig. 3 d, the addi-
tion of IL-2 during the in vitro peptide stimulation dra-
matically increased the fraction of proliferating cells.
Comparison of the percentage of CFSElow cells induced by
IL-2 alone versus peptides plus IL-2 demonstrated that al-
though IL-2 alone induced some CD4  T cell proliferation
nonspecifically, it definitely restored the proliferation of
peptide-specific CD4  T cells from viremic patients. This
experiment strongly suggests that the impaired proliferation
Table III. Proliferation and Cytokine Production by HIV Peptide–specific CD4  T Cells in Viremic Patients
Patient Peptide Sequence
Percent
CFSElow CD4  DBLFa CD69  IL-2  CD69  IFN-   IL-2 /IFN-   IL-2  IFN-  
111 G054 DRVHPVHAGPIAPGQ 0.02 0.0008  0.01 0.40  0.01  0.01 0.35
G067 WIILGLNKIVRMYSP 0.1 0.0005  0.01 0.12  0.01  0.01 0.15
112 G008 YKLKHIVWASRELER 0.3 0.001  0.01 0.10  0.01  0.01 0.15
G067 WIILGLNKIVRMYSP 0.1 0.0005  0.01 0.10  0.01  0.01 0.17
113 G065 PVGEIYKRWIILGLN 0.5 0.002  0.01 0.30  0.01  0.01 0.35
G067 WIILGLNKIVRMYSP 0.3 0.001  0.01 0.40  0.01  0.01 0.46
114 G053 AAEWDRVHPVHAGPI 0.5 0.002  0.01 0.10  0.01  0.01 0.19
G076 YKTLRAEQASQEVKN 0.4 0.002  0.01 0.10  0.01  0.01 0.17
115 G067 WIILGLNKIVRMYSP 0.4 0.002  0.01 0.20  0.01  0.01 0.21
G061 STLQEQIGWMTNNPP 0.2 0.0008  0.01 0.20  0.01  0.01 0.26
116 N048 LAFHHVARELHPEYF 0.35 0.001  0.01 0.12  0.01  0.01 0.15
G065 PVGEIYKRWIILGLN 0.3 0.001  0.01 0.11  0.01  0.01 0.17
117 G004 LDRWEKIRLPRGGKK 0.5 0.002  0.01 0.42  0.01  0.01 0.40
N036 WCYKLVPVEPDKVEE 0.4 0.002  0.01 0.31  0.01  0.01 0.30
118 N022 VDLSHFLKEKGGLEG 0.4 0.002  0.01 0.20  0.01  0.01 0.23
G057 PGQMREPRGSDIAGT 0.2 0.0008  0.01 0.23  0.01  0.01 0.24
Median 0.321 0.001 NA 0.21 NA NA 0.24
Values of percent CFSElow CD4  are the medians of five independent experiments. The percentages of cytokine production were measured after 12 h
after stimulation of patients’ PBMCs with HIV-specific peptides. The data depicted are the medians of three separate experiments. Values  0.01
indicate undetectable frequencies. NA, not applicable.
aDBLF, deduced baseline frequency derived from the 6-d CFSE-based proliferation assay.Younes et al. 1915
of CD4  T cells from viremic patients is not caused by a vi-
rus-mediated destruction of proliferating cells.
These results indicate that HIV-specific IL-2 and IL-2/
IFN-  CD4  T cells have the capacity to proliferate in re-
sponse to antigen, whereas IFN-   IL-2  HIV-specific
CD4  T cells, found mostly in viremic patients, have a di-
minished ability to divide that can be restored by exoge-
nous IL-2. Collectively, the data presented in Figs. 1, 2,
and 3 demonstrate that the lack of HIV-specific CD4  T
cell proliferation in viremic patients is caused neither by the
absence of HIV-specific cells nor by their virus-mediated
killing, but rather by their inability to produce IL-2.
HIV-specific CD4  T Cells with a Central Memory Phenotype
Are Detected Exclusively in Aviremic Patients. Next, we in-
vestigated to what extent the difference in the cytokine ex-
pression profile of CD4  T cells from viremic and aviremic
Figure 2. Four-parameter FACS® analysis of
epitope-specific CD4  T cells in aviremic and
viremic patients. (a and b) Detection of
epitope-specific CD4  T cells by intracellular
IL-2 and IFN-   staining of PBMCs from
aviremic (12C) and viremic (111) patients.
PBMCs were stimulated with 10  g/ml of
the indicated peptides or 200 ng/ml SEA, or
unstimulated (NS) for 12 h in the presence of
Brefeldin A. Numbers in each quadrant repre-
sent the frequency of CD69  cytokine . (c)
Frequency of CD69   IL-2   HIV-specific
CD4  T cells ( ) or CD69  IFN-   ( ) after
12 h of peptide stimulation of PBMCs from
aviremic and viremic patients. Single epitope
responses (two per patient) are depicted. Data
are derived from Tables II and III. Statistical
significance is determined by the exact Mann-
Whitney test. 5   104–105 CD4  T cell gated
events are shown. Data are representative of
three different experiments.Inhibition of HIV-specific CD4  T Cell Memory in Viremic Patients 1916
patients could be explained by the fact that these cells are at
distinct stages of effector/memory differentiation. It is now
well established that expression of CD45RA and CCR7
defines T cell subsets endowed with distinct proliferative
capacities and cytokine production profiles (21, 39). To as-
sess the impact of viremia on the differentiation state of
HIV-specific memory CD4  T cells, we analyzed their
phenotype in three aviremic (12C, 12B, and 11C) and
three viremic (111, 112, and 113) patients after in vitro
stimulation with the G067 peptide. Frequencies of CD69 
IL-2  or CD69  IFN-   CD4  T cells were quantified in
the different subsets using a six color flow cytometry assay.
Fig. 4 a shows a representative distribution of IL-2  and
IFN-   CD4  T cells among the CD4  T cell subsets from
an aviremic (12C) and a viremic (111) patient. Analysis of
cytokine production in patient 12C showed that IL-2–pro-
ducing cells are found in both the CD45RA  CCR7 
(0.06%) and CD45RA  CCR7  (0.1%) subsets. In the
viremic patient 111, none of the memory T cell subsets was
able to produce IL-2 upon peptide stimulation (as expected
from results presented in Figs. 1 and 2), whereas the major-
ity of IFN- –secreting cells had an effector memory
(CD45RA   CCR7 ) phenotype (0.2%). These results
were reproduced in an additional two aviremic (12B and
11C) and two viremic patients (112 and 113). Similar re-
sults were also obtained with other HIV peptides (G065,
G076, G054, and G008; not depicted).
These results do not exclude an overlap in the differenti-
ation state of IL-2–producing and nonproducing cells
found in the aviremic and viremic patients, respectively.
One possibility is that the latter belong to the Tem subset
but that their ability to produce IL-2 is impaired by their
persistent interaction with antigen.
HIV-specific IL-2–secreting CD4  T Cells in Aviremic Pa-
tients Stably Persist during the Course of HIV Infection.
Next, we evaluated in a longitudinal analysis the impact of
HIV viremia on the establishment/maintenance of HIV-
specific memory CD4  T cells. To carry out a longitudinal
analysis we selected highly conserved epitopes. Based on
the Los Alamos database (http://hiv-web.lanl.gov) and on
other studies (38, 40), sequence alignment of the G065-
G067 Gag region revealed that this sequence is highly con-
served in 208 HIV-1 strains of different clades, a character-
istic that validates the use of G065 and G067 peptides (94%
conservation in 37 clade B strains and 85% in total HIV-1
strains). Fig. 5 illustrates the frequency of HIV-specific
CD4  T cells detected by IL-2 and IFN-  at different time
points of infection in three aviremic and three viremic pa-
tients. Aviremic patients 12C, 12B, and 11C maintained
low viral load ( 50 copies/ml) from the initiation of
HAART until the most recent time points (i.e., 48 and 60
mo after HAART initiation). As shown in Fig. 5 a, signifi-
cant and reproducible frequencies of IL-2  and IL-2 /
IFN-   HIV-specific CD4  T cells were detected after
Figure 3. Correlation between the frequency of HIV-1 epitope-specific CD4  T cells monitored by IL-2
( ) or IFN-  cytokine ( ) deleted after 12 h and the frequency of CFSElow CD4  T cells after 6-d in vitro
proliferation in aviremic (a and b) and viremic (c) patients. Statistical significance of each correlation
was calculated using Spearman test. (d) IL-2 restores the proliferation of IFN-   IL-2  HIV-specific CD4 
T cells. PBMCs from viremic patients (111, 112, and 113) were labeled with CFSE and stimulated for 6 d
using a pool of HIV-specific peptides (10 overlapping peptides spanning the entire immunodominant region
GSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSIL) with or without
10 U/ml of IL-2. The numbers in each quadrant represent percentages of dividing T cells. 2–3   104 events
gated on live CD3  CD4  lymphocytes were collected and analyzed.Younes et al. 1917
stimulation of PBMCs from these patients with the G067
peptide. The overall frequency of IL-2  and IL-2 /IFN-  
G067-specific CD4  T cells remained stable for up to 5 yr
in patients 12C, 12B, and 11C (Fig. 5 a). Similar results
were obtained with G065- and G076-specific CD4  T cells
(Fig. 5 a, right).
Longitudinal analysis of PBMCs from viremic therapy-
failing patients (111, 112, and 113) showed a very differ-
ent pattern. As illustrated in Fig. 5 b, frequencies of
G067-specific IFN-   CD4  T cells predominate over
IL-2 CD4  T cells before HAART initiation (viral load
 75,000 copies/ml, time point 1). However, cytokine-
secreting cells were not found 1 yr after therapy initiation,
at time points when viremia was  1,000 copies/ml, in
the three therapy-failing patients (Fig. 5 b, middle, time
point 2). It is important to note that between time points
1 and 2, a median of two viral rebounds were observed in
the plasma of the three viremic patients analyzed. 5–6 yr
after HAART initiation, when viremia levels were
 30,000 copies/ml, we could again detect G067-specific
CD4  T cells secreting exclusively IFN-  (Fig. 5 b, right).
It appears that the presence of IFN-  /IL-2  HIV-spe-
cific CD4 T cells is restricted to time points of high vire-
mia in therapy-failing patients.
Proliferation of G067-specific CD4  T cells was mea-
sured (Fig. 5 c) at the same time points as in Fig. 5 b. In
therapy-failing patients 111, 112, and 113, G067-specific
CD4  T cells were detected before HAART initiation, as
illustrated by the significant percentages of CFSElow cells at
this time point (9, 2, and 6%, respectively; Fig. 5 c, left).
Figure 4. Six color FACS® analysis of HIV-specific CD4  T cells in
aviremic and viremic patients. (a) Representative pseudo color plots of
phenotypic analysis of G067-specific CD4  T cells in PBMCs from
aviremic (12C) and viremic (111) patients. Numbers above 0.01% in each
plot were considered positive. Patients’ PBMCs were stimulated with
G067 peptide for 12 h in the presence of Brefeldin A and stained with
biotinylated anti-CCR7 followed by streptavidin PE-Cy7, anti-CD4
APC-Cy7. Anti–IL-2 PE, anti–IFN-  APC, and anti-CD69 FITC were
added after fixation/permeabilization of the cells. 3   105 gated CD4  T
cell events are shown. (b) Schematic representation of IL-2  and/or
IFN-    CD4   T cell distributions and the expression of CCR7/
CD45RA in three aviremic and three viremic patients after stimulation
with G067 peptide. Data are representative of three different experiments.Inhibition of HIV-specific CD4  T Cell Memory in Viremic Patients 1918
Figure 5. Longitudinal analysis
of epitope-specific CD4  T cells
in three aviremic (11C, 12C,
and 13 C) and three viremic
(111, 112, and 113) patients by
intracellular IL-2 and IFN- 
staining and a CFSE-based pro-
liferation assay. (a) Pseudo color
plots from aviremic patients
stimulated with G067 peptide or
G065 and G076 peptide showing
the detection of IL-2/IFN-  and
IL-2 1 yr (Time 1) and 4–5 yr
(Time 2) after HAART initia-
tion. (b) Pseudo color plots
showing the frequency of G067-
specific CD4   T cells from
viremic patients by IL-2/IFN- 
ICS at time points before therapy
(Time 1), 1 yr (Time 2), and 6
yr (Time 3) after therapy initia-
tion. Numbers in each quadrant
represent the percentage of IL-2–
and/or IFN- –producing CD4 
T cells after stimulation with
G067 peptide. Data are repre-
sentative of three different ex-
periments. Media stimulation
was  0.01% in all experiments.
Between 5   104 and 2   105
events, gated on CD4  T cells,
were collected and analyzed. (c)
Pseudo color plots showing the
proliferative responses of G067-
specific CD4   T cells at the
same time points as in b. 2–5  
104 gated CD3  CD4  T cells
were collected after 6-d in vitro
incubation and analyzed.Younes et al. 1919
Interestingly, in the two patients (111 and 113) showing
the highest percentages of CFSElow CD4  T cells (9 and
6%, respectively), we could detect significant levels of IL-
2–secreting cells by direct ex vivo ICS (Fig. 5, b and c,
time point 1). It is important to note that despite the fact
that we could observe CD4  T cell proliferation at the two
later time points, the level of IL-2–producing cells was too
low to be detectable by ICS, demonstrating the sensitivity
of the CFSE-based proliferation assay. At later time points
(more than 1 yr after therapy initiation), G067-specific
CD4  T cells barely proliferated (average of 1.5% of CF-
SElow cells; Fig. 5 c, middle). This was particularly evident
after 6 yr of therapy, when the average proliferative re-
sponse was  0.1%.
Together, these results indicate that in the course of the
infection, HIV viral persistence lowers the frequency of IL-
2–producing HIV-specific CD4  T cells that possess a high
proliferative potential. Our results indicate that IL-2 pro-
duction by HIV-specific CD4  T cells is associated with
the persistence of a stable T cell memory compartment for
up to 5 yr. Moreover, it appears that IL-2  IFN-   HIV-
specific CD4  T cells are short-lived effector T cells.
Discussion
In this report we show that chronic viremia has a major
impact on the maintenance of antigen-specific memory T
cells endowed with proliferative and IL-2 secretion capaci-
ties. Cross-sectional and longitudinal analyses clearly
showed that peptide-specific CD4  T cell responses leading
to proliferation and IL-2 production were affected in
viremic patients. In contrast, a pool of CD4  memory T
cells, known to possess expansion potential, stably persists
in aviremic patients for up to 5 yr.
Previous studies reported a low frequency of antigen-
specific CD4  T cells in HAART-treated patients (17,
28–33). Our data contradict this notion because we have
been able to reproducibly detect frequencies of up to
0.1% of HIV-specific CD4  T cells. Two major factors
could account for this difference. First, our study popula-
tion mostly included patients who had been treated early
during HIV infection. As reported (15, 35, 36), it is likely
that early treatment prevents the depletion of HIV-spe-
cific CD4  T cells mediated by a direct cytopathic effect
of the virus or through chronic hyperimmune activation.
Moreover, exogenous loading of single peptides circum-
vents problems related to competition for MHC class II
binding that can be encountered when using peptide
pools and to inefficient protein processing and peptide
presentation when using intact proteins on frozen PBMCs.
In fact, we have observed that the sum of the prolif-
erative responses of individual peptide stimulations (i.e.,
the percentages of CFSElow CD4  T cells) was consistently
higher than the responses obtained with Gag protein or
with Gag and Nef peptide pools (unpublished data). In-
deed, we believe that our experimental strategy has al-
lowed us to overcome a major sensitivity barrier encoun-
tered in other assays. We estimate the proliferation assay
described here to be 100–1,000-fold more sensitive than
other currently used assays such as direct ex vivo ICS as-
says or MHC class II tetramers staining.
In aviremic patients, we established a positive correla-
tion (P   0.0001; R   0.81) between the frequency of
HIV-specific CD4  T cells secreting IL-2 and the CD4  T
cell proliferative responses. By contrast, there was no cor-
relation (P   0.4) between the percentages of HIV-spe-
cific, IFN-   IL-2  CD4  T cells and the level of virus-
specific proliferation in viremic patients. Thus, our data
corroborate previously published studies showing discrep-
ancies between the frequency of HIV-specific CD4  T
cells, as detected by IFN-  ICS, and the proliferative re-
sponses of HIV-specific CD4  T cells in viremic patients
(18–20). Our findings strongly support the view that the
reduction in HIV-specific lymphoproliferation in subjects
with active viral replication is not due to the absence of
HIV-specific CD4  T cells, but rather to their proliferative
“dysfunction,” caused by an inability to produce IL-2. In-
deed, the addition of IL-2 to these cells restored their pro-
liferative capacity (Fig. 3 d), which is abrogated in the
presence of high viremia. Interestingly, IL-2–mediated
rescue of nonproliferating HIV-specific CD4  T cells has
been observed in another cohort of viremic patients (41),
indicating that this phenomenon is not restricted to the
patients studied here. Although IL-2 could restore the
proliferative potential of IFN-   IL-2  CD4  T cells, re-
sults presented in Fig. 5 b strongly suggest that these cells
do not persist for a prolonged period of time in viremic
patients. In fact, HIV-specific IFN-   IL-2  CD4  T cells
are detected in the peripheral blood of viremic patients
only at time points when the viral load is elevated. Al-
though we cannot exclude the possibility that IFN- –pro-
ducing cells might reside in peripheral tissues (44) and re-
circulate through the blood only when viremia increases,
it is more likely that these cells are short lived and fail to
stably persist as long-term memory T cells.
The association of persistent exposure to high viral loads
with the disappearance of antigen-specific IL-2–producing
T cells has also been observed in a murine model. Fuller
and Zajac (42) recently showed that the frequency of lym-
phocytic choriomeningitis virus (LCMV)-specific CD4  T
cells producing IL-2 gradually decreased to undetectable
levels in mice chronically exposed to high viral loads, but
not in acutely infected mice. Similarly, LCMV-specific,
TCR transgenic CD4  T cells transferred to chronically in-
fected mice gradually lost the ability to secrete IL-2, to pro-
liferate, and to mediate B cell help (43). Importantly, trans-
fer of these cells into naive, antigen-free mice did not
restore their proliferative and IL-2 secretion ability,
strongly suggesting that this state of “unresponsiveness”
does not depend on the continued presence of virus, but
rather reflects intrinsic functional properties of the cells due
to previous exposure to high antigenemia (43).
A major finding of our study is that HIV-specific CD4 
T cells having a central memory phenotype (CD45RA 
CCR7 ) and secreting IL-2 are found in aviremic but not
viremic patients. A current model of memory T cell differ-
entiation predicts that persistent antigenic stimulation pre-
vents the establishment of a stable pool of functional long-Inhibition of HIV-specific CD4  T Cell Memory in Viremic Patients 1920
term memory cells (46). The proposed mechanism was
blocking, by persistent antigenic stimulation, of the differ-
entiation of effectors into long-lived memory cells of the
Tcm phenotype (46). An interpretation of our results ac-
cording to this model is illustrated in Fig. 6 a. Alternatively,
the “balance of growth and differentiation” model (47)
would suggest that activation of HIV-specific naive cells, or
of a small number of competent memory cells that are sus-
tained by self-renewal, frequently occurs, but that HIV an-
tigenemia in the therapy-failing patients rapidly induces
differentiation of the activated cells into short-lived effec-
tor cells (Fig. 6 b) after a burst of proliferation (48). It is
even possible that significant numbers of IL-2–producing
memory cells (Tcm and Tem) exist in viremic patients but
are rendered unresponsive through chronic stimulation-
mediated tuning of activation thresholds (48). According to
the results of our longitudinal study (Fig. 5), only viral
loads that exceed a certain threshold might break this unre-
sponsiveness, inducing proliferation/differentiation bursts
that end up in IFN-  only–producing cells. Similarly, some
of the IFN-  only–producing cells may regain capacity for
IL-2 production after the viral load is sufficiently reduced.
Alternatively, the absence of HIV-specific Tcm in
viremic patients could be explained by the fact that these
cells are highly susceptible to HIV-1 infection and might
ultimately be deleted by virus-mediated killing. Although
this possibility cannot be excluded, it should be noted that
exhaustion of IL-2–secreting CD4  T cells was also ob-
served in a non-CD4  T cell tropic infection such as
LCMV, suggesting that chronic stimulation rather than vi-
rus-mediated killing leads to the decline of IL-2  HIV-spe-
cific CD4  T cells.
We have observed that the cytokine secretion profile of
CD4   T cells with an effector memory phenotype
(CD45RA  CCR7 ) differs between viremic and aviremic
patients (Fig. 4). CD4  CD45RA  CCR7  T cells from
both aviremic and viremic patients produced IFN- , but
only cells from aviremic patients maintained the ability to
secrete IL-2. These results suggest that viral persistence not
only impedes the establishment/maintenance of central
memory CD4 T cells, but also alters the IL-2 production
capacity of effector memory cells.
The incapacity of HIV-specific CD4  T cells to produce
IL-2 probably may limit their ability to express T cell help
functions and may in particular affect anti-HIV CD8 T
cell–mediated responses. Defects in the differentiation of
HIV-specific CD8  T cells during HIV chronic infection
have been reported (39, 49) and this might be partly due to
lack of HIV-specific IL-2–secreting CD4  T cells. This is
supported by the recent finding that administration of IL-2
in chronically LCMV-infected mice rescued CD8  T cell
function and induced protection (50). The continuous an-
tigen-driven differentiation of proliferation-competent,
IL-2–secreting, HIV-specific CD4  T cells into IFN- 
only–producing cells with impaired proliferative and helper
ability might be either a mechanism of viral evasion from
immune control or merely a “normal” manifestation of
chronic immune activation.
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Figure 6. Alternative differentiation
schemes describing the impact of
HIV viremia on the size of memory/
effector CD4  T cell pools. (a) Ac-
cording to an extension of a general
differentiation scheme proposed for
CD8 T cells by Kaech et al. (refer-
ence 46), HIV-specific central
memory CD4  T cells (Tcm) are
derived in aviremic patients from
effectors (Tem1) elicited during the
acute phase of the infection. Tran-
sient activation episodes and IL-2
production–dependent self-renewal
would facilitate maintenance of a
stable steady state of this memory pool, in equilibrium with the Tem1 pool, after viremia has been controlled. When viremia persists, naive CD4  T cells
are constantly recruited and differentiate into effectors (Tem1). Constant antigenic stimulation prevents the differentiation of these effectors into Tcm.
Instead, they differentiate into more differentiated cells, Tem2, which lack the capacity to produce IL-2 and to self-renew, but are able to produce IFN- .
(b) Alternatively, the order of differentiation is always from naive to Tcm to Tem, as proposed by Lanzavecchia and Sallusto (reference 45). In aviremic
patients, Tcm and Tem1 are maintained, as in the other model, by self-renewal and occasional activation and differentiation events (limited ongoing
division counters the slow rate of death in the population). In the viremic patients, activation of HIV-specific naive and resting memory cells is enhanced,
but according to the “balance of growth and differentiation” model (see Discussion), accumulation of Tcm and Tem1 memory cells through self-renewal
division is prohibited because these proliferating cells are preferentially induced to differentiate into the IFN-  only–producing Tem2 cells. The relative
rates of self-renewal and differentiation are crudely reflected in the figure by the thickness of the arrows representing cellular flow. The relative size of the
different pools is indicated by the size of the circles representing these pools.Younes et al. 1921
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